Semaglutide Availability in India: A Clinical Reference

This is a clinical reference on semaglutide availability, mechanism, approved indications and interaction profile in the Indian market, built for prescribers and hospital pharmacy planning, not a source for individual dosing.

What is semaglutide approved for in India, and since when?

CDSCO's Subject Expert Committee for Endocrinology and Metabolism recorded semaglutide injection's original approval on 20 April 2022 and the oral tablet on 27 July 2020, both for glycaemic control in type 2 diabetes mellitus. A separate committee recommendation in December 2025 covered a synthetic-origin semaglutide injection at 15mg/3ml specifically for chronic weight management in adults with obesity or overweight and weight-related comorbidities.

Novo Nordisk's oral semaglutide tablet also received an additional approved indication in November 2025 to reduce major adverse cardiovascular event risk in type 2 diabetes patients at high cardiovascular risk, expanding its approved use beyond glycaemic control alone.

How does semaglutide actually work?

Semaglutide is a GLP-1 receptor agonist: it mimics the incretin hormone glucagon-like peptide-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. The appetite-suppressing effect that drives weight loss comes substantially from central GLP-1 receptor activity affecting satiety signalling, not from a direct metabolic or fat-burning mechanism.

This mechanism is why semaglutide's glycaemic and weight effects run together clinically even when the primary treatment goal is one or the other, and why stopping the drug typically sees appetite and weight trend back toward baseline, a well-documented pattern in the GLP-1 agonist literature.

What changed with patent expiry, and what does India's generic landscape look like now?

Novo Nordisk's core Indian patent on semaglutide expired in March 2026, and CDSCO-approved generic semaglutide from multiple Indian manufacturers launched the same month, a rare instance of a major biologic-adjacent therapy going generic in India within a few years of global launch. This is a direct consequence of India's patent law and CDSCO's separate bioequivalence approval pathway for each generic manufacturer, not an automatic or simultaneous market event.

Generic entry has moved monthly treatment cost meaningfully below the original branded price point, though the exact price gap varies by manufacturer, dose strength and delivery device, and changes as more manufacturers enter. A hospital pharmacy's procurement decision should track CDSCO's current approved-manufacturer list directly rather than a single cited price, since this market is moving fast.

What is semaglutide's actual side-effect profile?

Gastrointestinal effects dominate: nausea, vomiting, abdominal pain, constipation and diarrhoea are the most common reasons for discontinuation across clinical trials, with nausea reported in a substantial minority of patients on the diabetes-indication doses and a higher share at the weight-management dose. These effects are typically dose-related and often diminish with continued use, though they drive real discontinuation rates.

Less common but more serious risks include pancreatitis, diabetic retinopathy complications (specifically documented with rapid glycaemic improvement), gallbladder disease, and a boxed warning in some markets regarding thyroid C-cell tumour risk based on rodent studies, a signal not yet confirmed in humans but taken seriously in prescribing guidance.

What drug interactions matter for a prescribing team?

Semaglutide's most clinically significant interaction is added hypoglycaemia risk when combined with insulin or sulfonylureas, requiring dose adjustment of the other agent rather than avoidance of semaglutide itself. Its slowed gastric emptying effect can also alter the absorption timing of orally administered medications with a narrow therapeutic window.

A published case report documented an interaction between semaglutide and the antipsychotic ziprasidone affecting psychiatric symptom control, a reminder that GLP-1 agonists are now common enough in general medical populations that psychiatric and other specialty prescribers need to actively screen for concurrent use, not assume it away.

What does semaglutide availability mean for hospital pharmacy stocking?

Semaglutide has gone from a single-manufacturer, high-cost specialty drug to a multi-manufacturer, CDSCO-approved therapy with real volume potential inside two years, a shift few drug classes go through this fast. A hospital treating diabetes and obesity at any scale is now fielding patient demand for a drug that used to be effectively unstockable for most Indian hospital pharmacies on cost grounds alone.

That changes the calculus: a hospital that doesn't track which generic semaglutide manufacturers CDSCO has approved and stock at least one option sends a now-affordable, guideline-relevant prescription straight to an outside chemist. Our piece on prescription leakage and hospital revenue loss covers what that costs a hospital in continuity of care and pharmacy revenue, managed hospital pharmacy services covers the stocking model that keeps a fast-moving new-entrant drug like this available in-house, and pharmacy inventory management covers tracking a rapidly changing multi-manufacturer supply chain without dead stock.

Sources

1. 1SEC (Endocrinology & Metabolism) meeting dated 09.12.2025 — Central Drugs Standard Control Organisation
2. 2SEC (Endocrinology & Metabolism) meeting dated 06.11.2025 — Central Drugs Standard Control Organisation
3. 3Semaglutide — StatPearls — NCBI Bookshelf, National Institutes of Health
4. 4Semaglutide: Double-edged Sword with Risks and Benefits — PubMed
5. 5Glucagon-like Receptor-1 agonists for obesity: weight loss outcomes, tolerability, side effects, and risks — PMC, National Institutes of Health
6. 6Interaction of Semaglutide and Ziprasidone in a Patient With Schizophrenia: A Case Report — PMC, National Institutes of Health

This article is for informational purposes and is intended for clinicians and hospital administrators. It is not a substitute for professional medical advice, diagnosis or treatment, and contains no dosage instructions. Consult a qualified doctor for any individual patient's care.